Ibrutinib-Venetoclax Improves PFS in R/R Mantle Cell Lymphoma
(MedPage Today) -- SAN DIEGO -- Patients with relapsed/refractory mantle cell lymphoma (MCL) lived significantly longer without disease progression with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta), according to a randomized... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 14, 2023 Category: Hematology Source Type: news
Mantle Cell Lymphoma: Drug Combo Improves PFS Mantle Cell Lymphoma: Drug Combo Improves PFS
' In the countries where ibrutinib is indicated, this combination should be a new standard therapy for relapsed/refractory mantle cell lymphoma. 'MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Identifying the risk factors of suicidal ideation in patients with hematologic malignancies using a multidimensional approach - Kim J, Gang M.
BACKGROUND: Patients with hematologic malignancies have a 3.5-fold higher rate of suicide completion than the noncancer population, and the Hodgkin lymphoma has the highest suicide rate among all cancers. Although the risk factors for suicidal ideation amo... (Source: SafetyLit)
Source: SafetyLit - December 13, 2023 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news
ASH: Axi-Cel CAR T-Cell Treatment Effective in High-Risk Lymphoma Patients
TUESDAY, Dec. 12, 2023 -- For patients with relapsed or refractory large B-cell lymphoma, including those with comorbidities, the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) yields five-year... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 12, 2023 Category: Pharmaceuticals Source Type: news
New data for Roche ’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting& Exposition, 9-12 December ...
Source: Roche Media News - December 11, 2023 Category: Pharmaceuticals Source Type: news
New data for Roche ’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting& Exposition, 9-12 December ...
Source: Roche Investor Update - December 11, 2023 Category: Pharmaceuticals Source Type: news
ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission
(MedPage Today) -- SAN DIEGO -- Autologous stem-cell transplantation (ASCT) led to improved outcomes as compared with CAR T-cell therapy for patients with relapsed large B-cell lymphoma (LBCL) in complete remission, a retrospective analysis showed... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 11, 2023 Category: Hematology Source Type: news
Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH
Full analysis of multinational pivotal study results of golidocitinib in relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) (JACKPOT8 PART B) simultaneously published in The Lancet Oncology and presented in oral session at the 65th American Society of Hematology Annual Meeting... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 10, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news
New Data for Bispecific Antibody Epcoritamab (DuoBody ® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
- Data from Phase 1/2 EPCORE™ NHL-1 study show patients treated with epcoritamab experienced 82% overall response rates (ORR) including 63% complete response (CR) rates as presented at the 65th American Society of Hematology (ASH) congress - Follicular lymphoma is the second most common... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 9, 2023 Category: Pharmaceuticals Tags: TDS FVT TRI Source Type: news
Varicose veins could be a sign of CANCER, doctors warn - after treating 53-year-old woman with aggressive lymphoma
Doctors are warning that varicose veins could be a commonly missed sign of an aggressive form of non-Hodgkin lymphoma after treating a 53-year-old woman in China with the symptoms. (Source: the Mail online | Health)
Source: the Mail online | Health - December 8, 2023 Category: Consumer Health News Source Type: news
Study: Ditch the contrast agent in PET/MRI scans in children with lymphoma
F-18 FDG-PET/MRI scans without the use of a contrast agent should be the top choice for imaging children suffering from lymphoma, according to research presented recently at RSNA in Chicago. In a scientific session held November 30, Nils-Martin Bruckmann, MD, of University Hospital Düsseldorf in Germany, discussed a study that evaluated FDG-PET/MRI scans with and without the use of a contrast agent in children with newly diagnosed disease. The study authors found the contrast agent made no diagnostic difference.“The use of MRI contrast agents in F-18 FDG-PET/MRI examinations has no additional positive benefit for primar...
Source: AuntMinnie.com Headlines - December 7, 2023 Category: Radiology Authors: Will Morton Tags: Molecular Imaging Source Type: news
Radioimmunotherapy Tops ASCT in R/R Follicular Lymphoma Radioimmunotherapy Tops ASCT in R/R Follicular Lymphoma
A new trial from Italy challenges a decades-old assumption that autologous stem cell transplant is more effective than radioimmunotherapy for consolidation after follicular lymphoma relapse.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - December 5, 2023 Category: Drugs & Pharmacology Tags: Hematology-Oncology Source Type: news
Rituximab Maintenance Boosts Survival for Older Adults With MRD-Negative MCL
(MedPage Today) -- Maintenance therapy with rituximab yielded better survival outcomes for older patients with minimal residual disease (MRD) negativity after induction therapy for mantle cell lymphoma (MCL), results from the European Mantle Cell... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 5, 2023 Category: Hematology Source Type: news
CAR-T Therapies Not Cost-Effective for Diffuse Large B-Cell Lymphoma
MONDAY, Dec. 4, 2023 -- For patients with diffuse large B-cell lymphoma (DLBCL), the chimeric antigen receptor T-cell therapies (CAR-T) axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are not cost-effective, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 4, 2023 Category: Pharmaceuticals Source Type: news
FDA Approves Pirtobrutinib for Previously Treated CLL/SLL FDA Approves Pirtobrutinib for Previously Treated CLL/SLL
The approval is the second this year for the reversible, highly selective kinase inhibitor following a January approval in mantle cell lymphoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 4, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
